Prosecution Insights
Last updated: July 17, 2026

Temple University

10 pending office actions • 8 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days

Portfolio Summary

10
Total Pending OAs
6
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
2
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)Due later (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
8
Medium (80%)
1
Easy (10%)
1
Unknown (10%)

Rejection Statute Mix

BucketCases
§103 only6 (60%)
§102 only2 (20%)
§112 only1 (10%)
No statute on record1 (10%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
70% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
10% of docket
2
Business / Other
20% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

100 h
Manual time on pending OAs
20 h
Time saved (low, 20%)
35 h
Time saved (mid, 35%)
0.9 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ROBINSON, MIKHAIL O'DONNEL 1 57.5% +42.7%
PYLA, EVELYN Y 1 55.6% +47.4%
BUNNER, BRIDGET E 1 64.2% +19.8%
HUMPHRIES, NICHOLAS ADAM 1 35.5% +78.1%
BAUSCH, SARAE L 1 29.6% +44.2%
TURK, NEIL N 1 50.9% +44.4%
PERSONS, JENNA L 1 51.7% +58.4%
CHO, DAVID H 1 38.5% +72.7%
POLIAKOVA-GEORGAN, EKATERINA 1 64.3% +17.6%
JONES, LOGAN P 1 42.9% +32.6%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17997572 Epiprinter Technology and Methods of Use for Detecting Biomolecules BAUSCH, SARAE L

Interview Candidates (10)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17938209 BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE POLIAKOVA-GEORGAN, EKATERINA 84d overdue
18609070 Use of Short Chain Fatty Acids in Cancer Prevention PYLA, EVELYN Y 2d overdue
17945222 GAS BURNER ATTACHMENT JONES, LOGAN P 19d
18300468 PHARMACOLOGIC APPROACH FOR SUPPRESSION OF CORONAVIRUSES CHO, DAVID H 63d
17817696 METHOD OF DIAGNOSIS, PROGNOSIS, AND TREATMENT OF VITAMIN D DEFICIENCY AND VITAMIN D IMBALANCE AND DISEASES AND DISORDERS ASSOCIATED THEREOF TURK, NEIL N 69d
18793238 METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASE ROBINSON, MIKHAIL O'DONNEL
18515636 MonoMac-1 Cells Expressing CD16 and CD163 BUNNER, BRIDGET E
18549948 Noninvasive AAV Vectors For Highly Efficient Gene Delivery To The Nervous System HUMPHRIES, NICHOLAS ADAM

Top Art Units

Art UnitApps
1633 1
1647 1
1631 1
1699 1
1798 1
1693 1
1637 1
3762 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18793238 METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASE ROBINSON, MIKHAIL O'DONNEL §103 Non-Final OA Pending Aug 02, 2024
18609070 Use of Short Chain Fatty Acids in Cancer Prevention PYLA, EVELYN Y 1633 §103 Non-Final OA 2d overdue Pending Mar 19, 2024
18515636 MonoMac-1 Cells Expressing CD16 and CD163 BUNNER, BRIDGET E 1647 §102 Non-Final OA Pending Nov 21, 2023
18549948 Noninvasive AAV Vectors For Highly Efficient Gene Delivery To The Nervous System HUMPHRIES, NICHOLAS ADAM 1631 §103 Non-Final OA Pending Sep 11, 2023
17997572 Epiprinter Technology and Methods of Use for Detecting Biomolecules BAUSCH, SARAE L 1699 §103 Final Rejection Pending Oct 31, 2022
17817696 METHOD OF DIAGNOSIS, PROGNOSIS, AND TREATMENT OF VITAMIN D DEFICIENCY AND VITAMIN D IMBALANCE AND DISEASES AND DISORDERS ASSOCIATED THEREOF TURK, NEIL N 1798 §112 Final Rejection 69d Pending Aug 05, 2022
18577107 OLIGONUCLEOTIDES AND VIRAL UNTRANSLATED REGION (UTR) FOR INCREASING EXPRESSION OF TARGET GENES AND PROTEINS PERSONS, JENNA L §102 Non-Final OA Pending Jan 05, 2024
18300468 PHARMACOLOGIC APPROACH FOR SUPPRESSION OF CORONAVIRUSES CHO, DAVID H 1693 §103 Final Rejection 63d Pending Apr 14, 2023
17938209 BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE POLIAKOVA-GEORGAN, EKATERINA 1637 Other Final Rejection 84d overdue Pending Oct 05, 2022
17945222 GAS BURNER ATTACHMENT JONES, LOGAN P 3762 §103 Non-Final OA 19d Pending Sep 15, 2022

Managing Temple University's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month